Urapidil

Phase 3Small molecule

UUniversity Hospital, Strasbourg, France

Urapidil is one of 83 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

HypertensionActive, not recruiting

StrokePhase 3

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Urapidil

UUniversity Hospital, Strasbourg, France

Phase 3

2 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Apresoline

Novartis

Preclinical

7 5

Alphagan

AbbVie

Preclinical

—6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Disalcid

JJoslin Diabetes Center

Preclinical

1 9

Inderal

Mylan Pharmaceuticals Inc

Atorvastatin Calcium

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Not yet recruiting

Intracerebral Hemorrhage

NCT06635707

Clinical

Trials by Indication[1]

Hypertension2 trials

The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine

Terminated·UUniversity Hospital, Strasbourg, France·Phase 3·NCT02558023·14 enrolled

Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine

Unknown status·UUniversity Hospital, Strasbourg, France·Phase 3·NCT00409253·72 enrolled

Blood Pressure1 trial

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Completed·TThe George Institute·N/A·NCT00226096·404 enrolled

Hemodynamic1 trial

Effects of Different Kinds of Hypotensive Drugs on Dynamic Hemodynamic Changing in Patients Under Surgeries

Completed·—·N/A·NCT03497351·59 enrolled

CLE1 trial

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Withdrawn·UUniversity of Zurich·Phase 4·NCT03300479

Stroke1 trial

Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

Completed·TThe George Institute for Global Health, China·Phase 3·NCT03790800·2,425 enrolled

2 more indications

Elderly Patients1 trial

Effect of High vs. Low MAP Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery

Unknown status·HHu Anmin·N/A·NCT02857153·322 enrolled

Intracerebral Hemorrhage1 trial

Efficacy and Safety Study of Urapidil Alone or With Esmolol in Treating Acute Hypertensive Intracerebral Hemorrhage

Not yet recruiting·QQianfoshan Hospital··NCT06635707·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Urapidil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urapidil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urapidil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Strasbourg, France

Urapidil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hypertension2 trials

Blood Pressure1 trial

Hemodynamic1 trial

CLE1 trial

Stroke1 trial

Elderly Patients1 trial

Intracerebral Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News